The US has delivered the first 1,000 doses of Lenacapavir to Eswatini and Zambia, starting its African rollout despite major aid cuts.
Washington plans to fund two million doses by 2028 through partnerships with Gilead and the Global Fund. The twice-yearly drug is expected to sharply reduce new HIV infections
